Kratos Defense & Security Solutions, Inc. (KTOS): what the price assumes

In the published model solve dated 2026-Q2, anchored at $44.56, Kratos Defense & Security Solutions, Inc. (KTOS) is priced for today's economics sustained for ~28.9 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-07-29 · Exported: 2026-08-01 · Source: https://boothcheck.com/report/KTOS

Headline

FieldValue
TickerKTOS
CompanyKratos Defense & Security Solutions, Inc.
Current price$44.56/sh
CompositionService revenues 35% / Product sales 65%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Must persist for28.9y
Multiple paid298x operating income

Solve inputs: computed at a 11.1% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~3.4 years.

Reconcile: at the x-ray's 9.3% required return this reads ~23.1 years; the models below use their own rates.

How unusual the bet is: elevated

ReferenceValue
vs own history+0.91σ
sustained it ~10 years at this level14%
implied end-window share1%

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset5.34x1expensive
Earnings9.94x2expensive
Relative3.67x5expensive
Growth1.65x1expensive

Families that call it expensive: Asset, Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.1%); the inversion above states its own rate.

Per-Model Detail (n=9)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$0.00noNegative/zero FCF — equity value floored at $0
DCF Exit MultipleGrowth$0.00noNegative/zero FCF or EBITDA — equity value floored at $0
Relative ValuationRelative$14.133.15xyesP/E 48.4x (blended: static sector reference 22x + trailing (TTM) 284x), scenarios: 39.1x / 48.4x / 57.7x (bear / base = reference held flat / bull), EV/EBITDA 30.8x
Simple DDMGrowthno
Two-Stage DDMGrowthno
Simple Excess ReturnAsset$1.6926.37xyesBV/sh $18.18, ROE (TTM) 0.9%, ke 9.3% (excluded from median)
Two-Stage Excess ReturnAsset$0.8950.07xyes5yr excess ROE then converge to ke=9.3% (excluded from median)
Discounted Future Market CapGrowth$27.041.65xyesRev $1.4B, growth 22% (input: historical growth; tapered), Terminal P/S: 4.8x / 5.9x / 7.0x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair ValueRelative$5.957.49xyesEPS $0.17, growth 35% (input: historical EPS growth), PEG=8.12 (Overvalued)
Margin TrajectoryGrowthno
Earnings Power ValueEarnings$3.7911.76xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.02B × (1−21%) / WACC 9.1% → EPV (no growth)
Residual IncomeAsset$0.6370.73xyesBV $18.18 + 5yr PV of (ROE (TTM) 0.9% − Kₑ 9.3%) × BV; BV grows 0.6%/yr (excluded from median)
Graham NumberAsset$8.345.34xyes√(22.5 × EPS $0.17 × BVPS $18.18) — Graham's conservative floor
EV/EBITDA RelativeRelative$12.133.67xyesEBITDA $0.08B × sector EV/EBITDA 14.0x
FCF YieldEarningsno
SBC-Adj FCF YieldEarningsno
Ben Graham FormulaEarnings$5.498.12xyesEPS $0.17 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset$0.34131.06xyesBV $18.18 × (ROIC 0.2% / WACC 9.1%) (excluded from median)
P/Sales SectorRelative$15.092.95xyesRevenue $1.42B × sector P/S 2.0x
PEG Fair ValueRelative$6.386.98xyesEPS $0.17 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$1.8424.22xyesEPS $0.17 / required return 9.3% (Rf 4.3% + ERP 5.0%) (excluded from median)
Funds From Operations MultipleRelativeno
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Solvency

FieldValue
Net cash$1.3b
Net debt / NOPAT (after-tax)-70.90x (net cash)
Net debt / operating income (pre-tax)-56.01x (net cash)
Share count CAGR (dilution)9.2%
Burning cashyes

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

Bull Case

Start with the obvious risk, because the bull case has to earn its way past it: Kratos earns almost no profit today, with an operating margin of just 1.7%, and the price assumes that changes dramatically. The bull's answer is that the company is deliberately trading current margin for scale and market position in the fastest-growing corners of defense. The 10-K describes a growth philosophy where Kratos offerings and "affordability are an important competitive differentiator" on "large, new program and contract opportunities," and states the internal view that it is "better to have a large part" of a big program. Low-cost, high-volume defense hardware is a land-grab, and Kratos is grabbing land while margins are thin on purpose.

The backlog is the evidence the land-grab is working. Kratos exited the most recent quarter with a record consolidated backlog of $2.01 billion, $1.457 billion of it funded, on bookings of $605.2 million and a book-to-bill ratio of 1.6 to 1.0, meaning it is winning orders faster than it ships. The pipeline of opportunities has expanded to roughly $14 billion. Revenue grew 22.6% to $371.0 million in the quarter, with the Defense segment up 45.8% organically on hypersonic systems and Unmanned Systems growing on Valkyrie activity. A book-to-bill well above one is the leading indicator that the revenue line keeps climbing, and Kratos sits squarely in hypersonics, unmanned systems, and missile and space programs, the exact categories the Department of Defense is funding hardest.

The balance sheet is built to fund the buildout, which is the bull's structural point. Kratos carries roughly $1.46 billion in cash against minimal debt, a net-cash position that gives it the capacity to scale Valkyrie production and pursue the hypersonic drone program it is developing without a financing constraint. It raised that cash deliberately, completing a $1.2 billion equity offering in March 2026 to accelerate production. Management raised full-year 2026 revenue guidance to $1.7 billion to $1.76 billion on the strength of the bookings. Against defense-and-space peers Karman, Heico, and Astronics, Kratos is the affordability play in the highest-growth categories, and the bet is that as the volume programs mature, the thin margins widen and the company grows into a valuation that today looks impossible.

Bear Case

The structural fragility a holder should weigh is the capital structure itself, because the way Kratos funds its growth dilutes the very shareholders the growth is supposed to reward. In March 2026 the company sold roughly 14.3 million shares at $84.00 to raise about $1.2 billion, and the share count has been growing nearly 10% a year. A company that funds expansion by issuing equity is borrowing from future per-share value to buy present scale: even if revenue and total profit grow, the per-share claim is sliced thinner with each raise. The cash pile on the balance sheet is real, but it is shareholders' own diluted money, not cash the business generated, and a valuation already pricing decades of growth has no room to absorb continued dilution.

The profitability underneath the story is the hard number the multiple ignores. Kratos earns an operating margin of just 1.7%, so on a multiple basis the price sits at several hundred times current operating income, and the implied assumption is growth held at the self-funding ceiling for roughly three decades. The base rate for that is brutal: only about 14% of comparable fast-growers have sustained such a pace even ten years. The affordability strategy that wins the bull's land-grab is the same strategy that keeps margins razor-thin, because low-cost hardware is, by definition, low-margin hardware. The 10-K acknowledges results "may vary significantly from quarter to quarter," and a 1.7% margin leaves no buffer for a program delay, a cost overrun, or a bid protest.

The demand, however well-funded today, carries the full fragility of government contracting. The 10-K is explicit that the U.S. Government "provides a significant portion of our revenue, and our business could be adversely affected by changes in the fiscal policies of the U.S. Government," and that protracted competitive bidding and "competitor bid protests will continue," which can delay or cancel awards even after a successful bid. Backlog is a commitment, not cash, and defense priorities shift with budgets and administrations. The sell side is positive but the price has run ahead of even bullish targets: the mean target near $93 to $112 brackets today's price, with JP Morgan's June target at just $82 below it. The bet is not that Kratos fails. It is that the price pays for three decades of flawless, dilution-free execution from a company whose current margin is barely positive and whose growth is funded by issuing stock, and any stumble repriced against a several-hundred-times multiple has a very long way to fall.

Valuation

This is among the most aggressive valuations in the report-able universe, and the honesty of the section depends on naming that plainly. At today's price the market values Kratos at several hundred times its current operating income, which inverts to growth held at the self-funding ceiling for roughly three decades. That is not a forecast the company has earned; it is the assumption the price requires, and it sits well above what its fundamentals comfortably support. The relevant base rate is the sobering one: only about 14% of comparable fast-growers have sustained that pace even ten years, let alone thirty.

The method families could not disagree more completely, and the pattern is the entire story. The asset-value lens reads the price at more than six times where it lands, the earnings-power lens at nearly twelve times, the peer-multiple lens at more than four times, and even the forward-growth lens does not reach it. When no valuation family reaches the price, the price is a bet beyond what any standard frame supports. There is no valuation floor under this stock; it is pure narrative and momentum priced on the expectation that thin-margin, high-volume defense programs eventually compound into something the static methods cannot frame. The thin 1.7% margin is why the operating-income multiple is so extreme: the same revenue at a normalized defense margin would imply a far lower multiple, so the entire bet is that margins expand as the volume programs scale.

Solvency is genuinely strong, but it is strength the shareholders paid for. Kratos holds roughly $1.46 billion in cash against minimal debt, a net-cash fortress, but it built that fortress with a $1.2 billion equity raise that diluted holders nearly 10% in a year. So the balance sheet de-risks survival while the financing method erodes per-share value, which is the central tension. Against defense peers Karman and Heico, Kratos commands an even richer multiple on the strength of its backlog and hypersonic positioning, and the analyst targets near $93 to $112 sit around today's price with JP Morgan's at $82 below it. The street is underwriting the same long-duration, margin-expansion bet this framework isolates; the difference is that this report names it for what it is, a several-hundred-times multiple resting on three decades of assumed growth, rather than smoothing it into a target.

Catalysts

The first-quarter 2026 report drove the operating story forward but the stock fell on it, which captures the valuation tension. Revenue grew 22.6% to $371.0 million with a book-to-bill ratio of 1.6 to 1.0, record backlog of $2.01 billion, and a pipeline expanded to roughly $14 billion, and the Defense segment grew 45.8% organically on hypersonic systems. Management raised full-year 2026 revenue guidance to $1.7 billion to $1.76 billion, yet the shares sold off after the print, a sign the bar set by the multiple is hard to clear even on good results.

The capital raise is the catalyst that reshaped the share count. In March 2026 Kratos completed a roughly $1.2 billion public offering, selling about 14.3 million shares at $84.00, with proceeds earmarked to scale Valkyrie production. The trade-off is the catalyst to watch: the cash accelerates the buildout the bull case needs, but the dilution works against the per-share math, and how quickly the new capacity converts to profitable revenue is the test.

Program momentum is the forward driver. Kratos is developing a low-cost hypersonic drone capable of Mach 5-plus speeds, received a five-year MACH-TB contract that could reach $1.45 billion if all options are exercised, and continues to win unmanned and rocket-systems work. The sell side is broadly positive, with a Buy consensus and a mean target near $93 to $112, though JP Morgan's June target of $82 sits below the higher estimates. With the stock pricing decades of growth, each backlog and margin update is a high-stakes catalyst in either direction.

Peer Cohorts (Per Segment, With Filing Citations)

Kratos Government Solutions (KGS) (reported)

Unmanned Systems (US) (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Kratos Q1 2026 results and March 2026 offering, 2026 · Kratos Q1 2026 results, 2026 · Kratos Q1 2026 balance sheet, 2026 · Kratos 2026 guidance, 2026 · Kratos March 2026 public offering, 2026 · TipRanks and JP Morgan analyst notes, 2026 · Kratos March 2026 offering, 2026 · TipRanks and JP Morgan analyst consensus, 2026 · Kratos program announcements, 2026 · TipRanks and JP Morgan analyst coverage, 2026

View the full interactive KTOS report on boothcheck